The Life Spectrum of Asthma

Chicago, IL US
July 29, 2016 to July 31, 2016


 PDF icon Life Spectrum Credit Claiming Instructions


Stemming from the initiatives of AAAAI President Robert F. Lemanske, Jr., MD, FAAAAI, “The Life Spectrum of Asthma” will take place July 29-31, 2016 in Chicago. The agenda covers the entire life spectrum of asthma including inception and primary prevention, exacerbations, and progression to more severe forms of the disease:


Friday July 29
Asthma Inception and Progression
When and How Does Asthma Begin?: Robert F. Lemanske, MD FAAAAI
Immunology of Childhood Asthma: Patrick G. Holt, DSc
Early Life Events in Asthma Expression: Fernando D. Martinez, MD
Treatment Approaches to Preschool Wheezing Illnesses: Leonard B. Bacharier, MD FAAAAI

Saturday July 30
Reducing and/or Eliminating Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations: William W. Busse, MD FAAAAI
Immunopathologic Features of Asthma Exacerbations: Mario Castro, MD MPH
Acute Physiologic Characteristics and Long Term Clinical Consequences of Asthma Exacerbations: Stephen P. Peters, MD PhD FAAAAI
Precision Asthma Therapy: Picking the Right Biologic for the Right Patient: Thomas B. Casale, MD FAAAAI

Preventing and Treating Severe Asthma
Severe Asthma: Can it be Prevented or Reversed?: Sally E. Wenzel, MD FAAAAI
Airway Structural Alterations that Contribute to Severe Asthma:  Reynold A. Panettieri, Jr., MD
Novel Molecular Targets for Severe Asthma: Harald E. Renz, MD FAAAAI
Differentiating Difficult to Treat from Severe Asthma: Monica Kraft, MD FAAAAI

Sunday July 31
Asthma and COPD Overlap Syndrome (ACOS)
Moving from the Oslerian Paradigm to the Post-genomic Era: Are Asthma and COPD Outdated Terms?: Nicola A. Hanania, MD MS
Pathophysiologic Mechanisms of Asthma and COPD: Arthur F. Gelb, MD
Influence of Environmental Factors on Asthma and COPD: David B. Peden, MD MS FAAAAI
Precision Therapy for ACOS: Joe W. Ramsdell, MD

The course will provide allergy/immunology specialists with the tools they need to be recognized as the experts in the use of biologics and immunoinflammatory modulating agents to treat asthma. It will include a combination of lecture and interactive small-group learning activities to facilitate the transition of new concepts for asthma diagnosis and treatment into practice. A full agenda can be downloaded below.

Special Registration Pricing is Available for the Following Groups:

Allied Health: contact to register at the discounted rate of $100.
Fellows-in-Training: contact to register at no cost!

Abstract Submission
Abstract submission is now closed.

Special Accomodations
If you require dietary or other accomodations please indicate these at the bottom of this page before proceeding to checkout.

After registering for the meeting, visit the Sheraton Grand Chicago  site to reserve your hotel room. 

Target Audience

  • Allergist/immunologists
  • Allergy/immunology fellows-in-training
  • Researchers investigating the mechanisms and treatment of asthma

Learning Objectives

Upon completion of this activity, participants will be able to

  • Describe the mechanistic characteristics of, and appropriate treatment strategies for, asthma in young children.
  • Describe the biological characteristics of asthma exacerbations and the appropriate use of biologic therapies to treat them.
  • Define the the mechanistic and clinical characteristics of severe asthma that differentiate it from difficult to treat asthma.
  • Compare and contrast the biological and environmental characteristics of asthma and COPD and define appropriate treatment strategies for Asthma/COPD Overlap Syndrome.

Additional Information

Available credit: 
  • 12.50 Attendance
    Attendance credit.
  • 12.50 CME
    CME credit.
Course opens: 
Course expires: 
Event starts: 
07/29/2016 - 12:00pm CDT
Event ends: 
07/31/2016 - 11:00am CDT
Member cost:
Sheraton Grand Chicago
301 E. North Water Street
Chicago, IL 60611
United States

Planning Committee:

Robert F. Lemanske, MD FAAAAI
University of Wisconsin School of Medicine and Public Health
Dr. Lemanske disclosed no relevant financial relationships.

Thomas B. Casale, MD FAAAAI
University of South Florida
Dr. Casale disclosed the following relevant financial relationships: Sanofi-Regeneron, Teva, Novartis, Genentech, Boehringer-Ingelheim (advisory boards); Allerquest, Circassia, Xencor (consultant) 

Click here to review the AAAAI's Disclosure Policy. A full roster of planning committee members, faculty members, and course reviewers, including their disclosures of relevant financial relationships, is included below for download.

PDF icon life_spectrum_of_asthma_disclosures.pdf



Available Credit

  • 12.50 Attendance
    Attendance credit.
  • 12.50 CME
    CME credit.


Member cost:
Please login or register to take this course.

Required Hardware/software

  • Our system supports the two most recent versions of Safari, Google Chrome, and Firefox. Internet Explorer is not recommended.
  • Pop-ups must be enabled to allow access to all course content.
  • A PDF reader, such as Adobe Reader or Apple Preview, is required to review the required reading.